Lebrikizumab provides clinically meaningful response in face and hands in adults and adolescents with moderate-to-severe atopic dermatitis: ADhope 1 study
Skin · 09.11.2026 · 2026 (4) · 86-114
DOI: 10.61783/oegdv11214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Skin, online erschienen am 09.11.2026. Verfasst von Franz J. Legat und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Legat, F. J., Vestergaard, C., Seneschal, J., Weidinger, S., Wollenberg, A., Irvine, A., Agell, H., Bancells, J. V., Sapena, V., & Thaçi, D. (2026). Lebrikizumab provides clinically meaningful response in face and hands in adults and adolescents with moderate-to-severe atopic dermatitis: ADhope 1 study. Skin, 2026(4), 86-114. https://doi.org/10.61783/oegdv11214
Vancouver
Legat FJ, Vestergaard C, Seneschal J, Weidinger S, Wollenberg A, Irvine A, et al. Lebrikizumab provides clinically meaningful response in face and hands in adults and adolescents with moderate-to-severe atopic dermatitis: ADhope 1 study. Skin. 2026;2026(4):86-114. doi:10.61783/oegdv11214
BibTeX
@article{Legat2026,
author = {Legat, Franz J. and Vestergaard, Christian and Seneschal, Julien and Weidinger, Stephan and Wollenberg, Andreas and Irvine, Alan and Agell, Helena and Bancells, Júlia Valls and Sapena, Victor and Thaçi, Diamant},
title = {Lebrikizumab provides clinically meaningful response in face and hands in adults and adolescents with moderate-to-severe atopic dermatitis: ADhope 1 study},
journal = {Skin},
year = {2026},
volume = {2026},
number = {4},
pages = {86--114},
doi = {10.61783/oegdv11214}
}
EUVIMED